Genetic and clinical study of myeloperoxidase's association with coronary artery disease

Lina N Adam; Omar A M Al-Habib; Ashur Y Oraha; Mudhir S Shekha

doi:10.1186/s43044-024-00457-7

Genetic and clinical study of myeloperoxidase's association with coronary artery disease

Egypt Heart J. 2024 Feb 21;76(1):27. doi: 10.1186/s43044-024-00457-7.

Authors

Lina N Adam¹, Omar A M Al-Habib², Ashur Y Oraha³, Mudhir S Shekha^{4

5}

Affiliations

¹ Department of Biology, College of Science, University of Zakho, Duhok, Kurdistan Region, Iraq. lina.adam@uoz.edu.krd.
² Department of Biology, College of Science, University of Nawroz, Duhok, Kurdistan Region, Iraq.
³ Department of Cardiothoracic and Vascular Surgery, College of Medicine, University of Duhok, Duhok, Kurdistan Region, Iraq.
⁴ Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden. mudhir.shekha@mcb.uu.se.
⁵ Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq. mudhir.shekha@mcb.uu.se.

Abstract

Background: Unraveling myeloperoxidase's (MPO) correlation with coronary artery disease (CAD) and genetic variations, this study seeks to enhance diagnostic precision and therapeutic strategies.

Results: CAD patients were found to be older and more male than controls. Several clinical parameters, including glucose, total bilirubin, alkaline phosphatase, creatinine, and troponin levels, showed significant variations. Moreover, CAD patients had lower red cell distribution width (RDW%) and mean platelet volume (MPV) than controls. Serum MPO levels did not differ significantly between CAD patients and controls, and no correlation was found with other clinical parameters except for glucose, creatinine, and total bilirubin.

Conclusions: The data suggest that serum MPO levels are not substantially related to CAD patients, as indicated by lower MPO levels in CAD patients compared to controls. While highlighting the potential of MPV and RDW% as predictors of severe atherosclerosis in CAD. Further research is needed to validate the diagnostic and prognostic value of RDW%, MPV, and MPO levels in CAD.

Trial registration: 15092021-9-12. Registered 15 September 2021.

Keywords: Biomarkers; Cardiovascular risk; Coronary artery disease (CAD); Genetic variation; Myeloperoxidase (MPO).